Company profile: Nektar Therapeutics
1.1 - Company Overview
Company description
- Provider of therapeutics based on an advanced polymer conjugate chemistry platform, including Rezpegaldesleukin (REZPEG/NKTR-358), a regulatory T cell stimulator targeting the IL-2 receptor complex to address immune imbalances in autoimmune and inflammatory diseases; PEG-CSF Protein to modulate inflammation resolution; and a bivalent TNFR antibody that selectively stimulates TNFR2 to enhance T regulatory cell function.
Products and services
- PEG-CSF Protein: A polyethylene glycol-modified (PEGylated), inflammation-modulating protein architected to influence resolution processes, applicable in acute and chronic inflammation
- Rezpegaldesleukin (REZPEG/NKTR-358): A receptor-targeted regulatory T cell stimulator that engages the IL-2 receptor complex to address immune system imbalances in autoimmune and inflammatory diseases
- TNFR Antibody: A bivalent, receptor-selective antibody that stimulates TNFR2 activity to enhance T regulatory cell function, potentially modulating autoimmune diseases
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Nektar Therapeutics
Dewpoint Therapeutics
HQ: United States
Website
- Description: Provider of condensate-modifying drugs and an AI-powered drug discovery platform focused on biomolecular condensates. Offers therapies targeting TDP-43 for ALS and neurodegenerative diseases and beta catenin for cancers such as colorectal cancer. Engages in partnerships with pharmaceutical companies to develop drugs for cardiovascular diseases, insulin resistance, and oncology.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Dewpoint Therapeutics company profile →
Cristcot
HQ: United States
Website
- Description: Provider of drug delivery systems that combine products and specialty drug formulations, including Novel Rescue for UC Flares, a drug in Phase 3 clinical trials designed to achieve clinical remission in ulcerative colitis via mucosal healing within 4 weeks, and a patented hydrocortisone acetate suppository delivered with the Sephure applicator for consistent drug delivery and rapid bioavailability.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Cristcot company profile →
ProAxsis
HQ: United Kingdom
Website
- Description: Provider of laboratory-based immunoassays and rapid point-of-care tests for the capture, detection, and measurement of active protease biomarkers of disease, incorporating patented ProteaseTags smart molecules that selectively trap active proteases and deliver a visual readout in complex biological samples.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full ProAxsis company profile →
Nanalysis
HQ: Canada
Website
- Description: Provider of portable benchtop nuclear magnetic resonance (NMR) spectrometers and supporting software for biotech, pharmaceutical, research, and education applications. Offerings include 100 MHz and 60 MHz NMR spectrometers, NMReady-CONNECT for remote control/monitoring, pulse sequence design, time-based kinetics experiments, and IQ/OQ modules for performance validation and regulatory compliance.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Nanalysis company profile →
ALPCO
HQ: United States
Website
- Description: Provider of testing solutions for scientists and healthcare professionals, delivering molecular and immunodiagnostic assays across gastroenterology, allergy/infectious disease, diabetes and obesity, bone metabolism, and antibodies/antigens. Offerings include fecal calprotectin and pancreatic elastase assays, IgE allergy testing, and multiplex PCR detecting CT/NG/MG to inform research and quality of care.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full ALPCO company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Nektar Therapeutics
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Nektar Therapeutics
2.2 - Growth funds investing in similar companies to Nektar Therapeutics
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Nektar Therapeutics
4.2 - Public trading comparable groups for Nektar Therapeutics
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →